

REVENIO

Revenio Group Corporation: Revenio Group's financial reporting and Annual General Meeting in 2022

Revenio Group Corporation, Stock Exchange Release, November 26, 2021 at 9:00

REVENIO GROUP'S FINANCIAL REPORTING AND ANNUAL GENERAL MEETING IN 2022

Revenio Group Corporation will publish the following financial reports during 2022:

- Financial Statements bulletin regarding 2021 on Thursday, February 10, 2022
- Interim Report 1-3/2022 on Thursday, April 28, 2022
- Interim Report 1-6/2022 on Thursday, August 4, 2022
- Interim Report 1-9/2022 on Thursday, October 27, 2022

The financial statements bulletin, half-yearly report and interim reports will be published at approximately 9 am Finnish time on the above dates.

Report by the Board of Directors and Financial Statements 2021

Report by the Board of Directors and Financial Statements for 2021 will be published on the Group's website <https://www.reveniogroup.fi/en/> during week 11 in 2022. At the same time, the company will publish a Corporate Governance Statement and a Remuneration Report for 2021.

Annual General Meeting 2022

The Annual General Meeting is planned to be held on Friday, April 8, 2022. The Board of Directors will give later a separate notice of the Annual General Meeting.

A shareholder, who wishes to include an item on the agenda of the Annual General Meeting, shall submit the request in writing to the company's Board of Directors by February 23, 2022. Such requests including the reasoning, or a resolution proposal can be submitted to the address: Revenio Group Corporation / Board of Directors, Äyritie 22, FI-01510 Vantaa, Finland.

Revenio Group Corporation

For further information, please contact:

CFO Robin Pulkkinen, tel. +358 50 505 9932

robin.pulkkinen@revenio.fi

www.revenio.fi

REVENIO

For further information, please contact:

Jouni Toijala, CEO, tel. +358 50 484 0085
jouni.toijala@revenio.fi
www.revenio.fi

Revenio Group in brief

Revenio is a leading company in ophthalmological devices and software solutions. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), retinal imaging devices, and perimeters under the iCare brand. In addition, the Group's eye care software platform Oculo brings together clinical communication, telehealth, remote patient monitoring, and data analytics capabilities.

In 2020, the Group's net sales totaled EUR 61.1 million, and its operating profit amounted to EUR 17.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

[Revenio Group Corporation: Revenio Group's financial reporting and Annual General Meeting in 2022](#)